<PAGE> 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report: July 17, 1997
(Date of earliest event reported)
LIDAK PHARMACEUTICALS
(Exact name of registrant as specified in its charter)
CALIFORNIA
(State or other jurisdiction of incorporation)
0-18734 33-0314804
(Commission File Number) (IRS Employer Identification No.)
11077 North Torrey Pines Road, La Jolla, California 92037
(Address of principal executive offices) (Zip code)
(619) 558-0364
(Registrants telephone number, including area code)
<PAGE> 2
Item 5. OTHER EVENTS
The registrant incorporates by reference herein the press release dated
July 17, 1997, attached hereto as Exhibit 99.
Item 7. Financial Statements and exhibits
(c) Exhibits
(i) Exhibit 99 - Press Release dated July 17, 1997
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
LIDAK PHARMACEUTICALS
Date: July 23, 1997 By: /s/ David H. Katz
-----------------------------------
David H. Katz, M.D.
President & Chief Executive Officer
<PAGE> 1
EXHIBIT 99
LIDAK PHARMACEUTICALS
NEWS RELEASE
DATE: JULY 17, 1997 CONTACT: LISA DAWN KATZ
DIRECTOR, CORPORATE
RELEASE DATE: IMMEDIATE COMMUNICATIONS &
INVESTOR RELATIONS
LIDAK PHARMACEUTICALS
(619) 558-0364, EXT. 256
DAVID H. KATZ, M.D.
PRESIDENT/CEO
LIDAK PHARMACEUTICALS
(619) 450-1538
LIDAK PHARMACEUTICALS RECEIVES NEW PATENT ALLOWANCE ON
HUMAN IMMUNE SYSTEM IN NON-HUMAN ANIMAL
LA JOLLA, CALIFORNIA -- July 17, 1997 -- LIDAK Pharmaceuticals (NASDAQ
NNM: LDAKA) announced today that it had received notification of allowance from
the U.S. Patent and Trademark Office for patent application #08/543,449 for
Human Immune System in Non-Human Animal. This new patent is a continuation to
patent #5,476,996 which issued in 1995 and is assigned to LIDAK. The original
patent covered a strain of mouse known as C.B-17 scid/scid into which human
peripheral blood leukocytes had been engrafted, thereby creating a model of the
human immune system. The term scid is an acronym for Severe combined Immune
Deficient. The new patent will extend coverage to other strains of scid/scid
mice and production of human antibodies in these mice, including monoclonal
antibodies, and provides protection from individuals using these experimental
models without license.
Mouse models covered by the LIDAK patents are useful in conducting
immunological research and are particularly useful compared to primates for
testing drugs against HIV (Human Immunodeficiency Virus). Mice prepared using
the method in the patents can be readily infected with the human virus yet are
more flexible and far less expensive than primate models. These mouse models are
also useful for producing human antibodies. LIDAK makes non-exclusive licenses
to the model available to interested parties. Southern Research Institute in
Birmingham, Alabama conducts commercial testing for clients using the LIDAK
model under license.
Commenting on the announcement, David H. Katz, M.D., LIDAK's president and
chief executive officer, stated, "This patent reflects many years of
groundbreaking research in the development of novel animal models that can more
accurately and inexpensively mimic the human immune system. The hu-PBL-SCID
model continues to support scientific advancements in the treatment of human
immune system diseases, particularly HIV and AIDS."
LIDAK Pharmaceuticals is developing therapeutic products against virally
caused diseases, inflammatory disorders and cancer. LIDAK recently completed the
patient enrollment and treatment portion of two Phase 3 clinical trials studying
its proprietary drug, n-docosanol (LIDAKOL(R)) as a treatment for oral herpes.
The studies were conducted on over six hundred patients at 22 clinical sites
around the United States. The Company anticipates data availability during the
summer of 1997, as previously reported.
# # #
The information contained in this press release should be reviewed in
conjunction with the Company's Annual Report on Form 10-K and other publicly
available information regarding the Company, copies of which are available from
the Company upon request. Such publicly available information sets forth many
risks and uncertainties related to the Company's business, including risks and
uncertainties related to drug development and clinical trials.
